The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China

References

• World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2021 Licence: CC BY-NC-SA 30 IGO; 2021.
   Google Scholar
• Borisov SE, Dheda K, Enwerem M. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi:10.1183/13993003.00387-2017
   PubMed Web of Science ®Google Scholar
• Gao M, Gao J, Xie L, Wu G, Li L. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2020;27(4):597–602. doi:10.1016/j.cmi.2020.06.004
   Web of Science ®Google Scholar
• Nimmo C, Naidoo K, O’Donnell M. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(24):2376–2377.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013;67(3):957–963. doi:10.1007/s12013-013-9589-5
   Web of Science ®Google Scholar
• Javaid AAU, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect. 2018;24(6):612–617. doi:10.1016/j.cmi.2017.09.012
   Web of Science ®Google Scholar
• Nagel S, Streicher EM, Klopper M, Warren RM, Van Helden PD. Isoniazid resistance and dosage as treatment for patients with tuberculosis. Curr Drug Metab. 2017;18(11):1030–1039. doi:10.2174/1389200218666171031121905
   Web of Science ®Google Scholar
• Jurgen P, Angeby K, Sturegard E, et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol. 2010;48(5):1853. doi:10.1128/JCM.00240-10
   Web of Science ®Google Scholar
• Rampersad T, Makume M, Sobia P, Sturm AW. A high throughput methodology for susceptibility testing of Mycobacterium tuberculosis isolates. J Microbiol Methods. 2018;146:64. doi:10.1016/j.mimet.2018.02.001
   Web of Science ®Google Scholar
• Kuhlin J, Forsman LD, Manoj M, Nordvall MJ, Bruchfeld J. Genotypic resistance of pyrazinamide but not MIC is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2020;73(9):e3511–e3517.
   Web of Science ®Google Scholar
• Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–528. doi:10.1183/09031936.00073611
   PubMed Web of Science ®Google Scholar
• Lee J, Armstrong DT, Ssengooba W, et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother. 2014;58(1):11–18. doi:10.1128/AAC.01209-13
   PubMed Web of Science ®Google Scholar
• Wu X, Yang J, Tan G, Liu H, Yu F. Drug resistance characteristics of Mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. Front Cell Infect Microbiol. 2019;9:345. doi:10.3389/fcimb.2019.00345
   Web of Science ®Google Scholar
• World Health Organization. WHO Operational Handbook on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO; 2020.
   Google Scholar
• Chinese anti-Tuberculosis Association. Chemotherapy guidelines on drug-resistant Tuberculosis (2015). Chin Anti-TB J. 2019;37(5):421–469.
   Google Scholar
• World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis-2011 Update. Geneva, Switzerland: World Health Organization; 2011.
   Google Scholar
• Lange C, van Leth F, Mitnick C, Dheda K, Günther G. Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respir Med. 2018;6(4):246–248. doi:10.1016/S2213-2600(18)30104-8
   PubMed Web of Science ®Google Scholar
• Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25(2):190–195. doi:10.1016/j.cmi.2018.07.012
   Web of Science ®Google Scholar
• Sun W, Wu Z, Ying Z, Fan X, Fan L. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China. BMC Infect Dis. 2021;21(1). doi:10.1186/s12879-021-06553-2
   Web of Science ®Google Scholar
• Ns A, Pks A, Us A, Aj A, Rg B. Fluoroquinolone drug resistance among MDR-TB patients increases the risk of unfavorable interim microbiological treatment outcome: an observational study. J Glob Antimicrob Resist. 2020;24:40–44.
   Web of Science ®Google Scholar
• Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(10):1335–1343. doi:10.5588/ijtld.11.0811
   PubMed Web of Science ®Google Scholar
• Byeong-Ho J, Kyeongman J, Hye Y, et al. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment. J Antimicrob Chemother. 2015;70(11):3127–3133. doi:10.1093/jac/dkv215
   Web of Science ®Google Scholar
• Ska B, Kj C, Ar A. Variations in rifampicin and isoniazid resistance-associated genetic mutations among drug naive and recurrence cases of pulmonary tuberculosis - ScienceDirect. Int J Infect Dis. 2020;103:56–61.
   Web of Science ®Google Scholar
• Huyen MN, Cobelens FG, Buu TN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2013;57(8):3620–3627.
   Web of Science ®Google Scholar
• Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother. 2019;63(5). doi:10.1128/AAC.00055-19
   Web of Science ®Google Scholar
• Hung W, Yu M, Chiang Y, et al. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Int J Tuberc Lung Dis. 2014;18(5):601–606. doi:10.5588/ijtld.13.0268
   Web of Science ®Google Scholar
• van der Galiën R, Boveneind-Vrubleuskaya N, Peloquin C, Skrahina A, Touw D, Alffenaar J. Pharmacokinetic modeling, simulation, and development of a limited sampling strategy of cycloserine in patients with multidrug-/extensively drug-resistant tuberculosis. Clin Pharmacokinet. 2020;59(7):899–910. doi:10.1007/s40262-020-00860-8
   Web of Science ®Google Scholar
• Mamatha HG, Shanthi V. Baseline resistance and Cross-resistance among fluoroquinolones in multi drug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory. J Glob Antimicrob Resist. 2017;12:5–10.
   PubMed Web of Science ®Google Scholar
• Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother. 2009;53(12):5064–5068. doi:10.1128/AAC.00851-09
   PubMed Web of Science ®Google Scholar
• Malinga L, Brand J, Jansen V, Cassell G, Van D. Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa. Int J Mycobacteriol. 2016;5(Supplement 1):S36–S37. doi:10.1016/j.ijmyco.2016.11.020
   Google Scholar